Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Short term Debt for 7 consecutive years, with $59.4 million as the latest value for Q2 2025.

Quarterly Short term Debt changed N/A to $59.4 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $59.4 million through Jun 2025, changed N/A year-over-year, with the annual reading at $3.1 million for FY2020, 8.82% down from the prior year.
Short term Debt for Q2 2025 was $59.4 million at Myriad Genetics, down from $104.1 million in the prior quarter.
The five-year high for Short term Debt was $104.1 million in Q2 2021, with the low at $59.4 million in Q2 2025.